Nirav Dhanesha Lab - LSU Health Shreveport

Nirav Dhanesha, PhD

Assistant Professor
Graduate Program Director
Department of Pathology and Translational Pathobiology

Education / Training
B.Pharm (2001-2005) – North Gujarat University, India
M.Pharm (2005-2007) –Gujarat University, India.
PhD (2010-2014) – KSV University and Zydus Research Center, India
Post‐Doctoral Fellow (2014-2019)– University of Iowa

News

July 2026: Congratulations to Nilesh on securing an NIH K99/R00 Pathway to Independence Award, the first K99 award received at LSU Health Shreveport. LSU Health Shreveport News | KTBS News
May 2026: Congratulations to Evan on receiving an ATVB Travel Award to attend Vascular Discovery 2026.
May 2026: Congratulations to Ukti on winning 1st Place in Genomics and Epigenetics in the SVS Foundation VRIC Poster Competition at Vascular Discovery 2026.
May 2026: Congratulations to Ukti on being selected as a finalist for the ATVB Emerging Scientist Award for Women at Vascular Discovery 2026.
March 2026: Our study entitled “Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis” was published in Blood Advances.
February 2026: Congratulations to Evan on receiving the D. Neil Granger Outstanding Predoctoral Student Award.
February 2026: Congratulations to Nilesh on receiving the D. Neil Granger Outstanding Postdoctoral Student Award.
December 2025: Congratulations to Nirvana on being selected for an oral presentation entitled “The Receptor Tyrosine Kinase EphA2 Promotes Thrombogenesis and Impairs Thrombus Resolution in DVT” at the 67th ASH Annual Meeting and Exposition, Orlando, FL.
December 2025: Congratulations to Nirvana on receiving an ASH Abstract Achievement Award from the American Society of Hematology at the 67th ASH Annual Meeting and Exposition, Orlando, FL.
December 2025: Congratulations to Nirvana on receiving an ASH Abstract Achievement Award from the American Society of Hematology at the 67th ASH Annual Meeting and Exposition, Orlando, FL.
November 2025: Congratulations to Harpreet Kaur on being selected for a poster presentation at the Society for Neuroscience (SfN) 2025.
November 2025: Congratulations to Harpreet Kaur on receiving the CCDS Malcolm Feist Postdoctoral Fellowship.
October 2025: Congratulations to Dr. Dhanesha on being invited to deliver an oral presentation at the Department of Pharmacology, Tulane School of Medicine, New Orleans, LA.
October 2025: Congratulations to Nilesh on receiving the Outstanding Postdoctoral Fellow Award from the Department of Pathology and Translational Pathobiology.
September 2025: Congratulations to Harpreet Kaur on winning Second Prize in the poster presentation during National Postdoc Appreciation Week 2025.
September 2025: Congratulations to Harpreet Kaur on receiving Third Prize in the BRAID Conference poster presentation.
July 2025: Congratulations to Harpreet Kaur on the publication of her study, “Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery After Subarachnoid Hemorrhage,” in Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
July 2025: Congratulations to Evan on receiving the Multidisciplinary Training in Cardiovascular Pathophysiology T32 Fellowship.
June 2025: Congratulations to Nilesh on receiving an Early Career Award at the ISTH 2025 Congress, Washington, D.C.
June 2025: Congratulations to Nilesh on being selected for an oral presentation entitled “Neutrophil CD14 Promotes Deep Vein Thrombus Formation via Procoagulant Platelet Formation” at the ISTH 2025 Congress, Washington, D.C.
June 2025: Congratulations to Dr. Dhanesha on delivering an oral presentation entitled “Hepatic Oxalate Overproduction Exacerbates DVT in Metabolic Dysfunction-Associated Steatohepatitis” at the ISTH 2025 Congress, Washington, D.C.
April 2025: Congratulations to Harpreet Kaur on the publication of her study, “Prolyl Hydroxylase Inhibitor Desidustat Improves Stroke Outcomes via Enhancing Efferocytosis in Mice with Chronic Kidney Disease,” in Experimental Neurology.
February 2025: Harpreet Kaur presented her work entitled “Prolyl Hydroxylase Inhibitor Desidustat Improves Stroke Outcomes by Enhancing Microglial Efferocytosis in Mice with Chronic Kidney Disease” at the International Stroke Conference 2025.
February 2025: Congratulations to Nilesh on winning First Prize in Poster Presentation at the 2025 Malcolm Feist Cardiovascular Research Symposium.
January 2025: Congratulations to Nilesh on receiving an American Heart Association (AHA) Postdoctoral Fellowship Award.
December 2024: Congratulations to Nilesh on receiving an ASH Abstract Achievement Award from the American Society of Hematology at the 66th ASH Annual Meeting and Exposition, San Diego, CA.
October 2024: Congratulations to Nilesh on being selected for an oral presentation entitled “Targeting Neutrophil CD14 Inhibits Deep Vein Thrombus Formation and Enhances Thrombus Resolution Following Inferior Vena Cava Stenosis in Mice” at the 66th ASH Annual Meeting and Exposition, San Diego, CA.
September 2024: Congratulations to Harpreet Kaur on receiving First Prize in the BRAID Conference poster presentation.
September 2024: Congratulations to Harpreet Kaur on receiving the Junior Investigator Award at the International Stroke Conference (ISC).
August 2024: Our study entitled “Enhanced Venous Thrombosis and Hypercoagulability in Murine and Human Metabolic Dysfunction-Associated Steatohepatitis” was published in the Journal of Thrombosis and Haemostasis.
July 2024: Congratulations to Nilesh on receiving the Center for Cardiovascular Diseases and Sciences (CCDS) Malcolm Feist Cardiovascular Research Postdoctoral Fellowship (Intramural).
May 2024: Congratulations to Dr. Dhanesha on being invited to deliver an oral presentation at Vascular Discovery: From Genes to Medicine Scientific Sessions in Chicago, IL.
April 2024: Our study entitled “Interactions Between Integrin α9β1 and VCAM-1 Promote Neutrophil Hyperactivation and Mediate Poststroke DVT” was published in Blood Advances.
February 2024: Congratulations to Harpreet Kaur on being selected for an Oral Presentation at the International Stroke Conference in Phoenix, Arizona, for her work entitled, “Integrin α9β1 and VCAM-1 Interaction Promotes Neutrophil Hyperactivation and Cognitive Decline Following Subarachnoid Hemorrhage.”
January 2024: Congratulations to Harpreet Kaur on receiving the American Heart Association (AHA) Postdoctoral Fellowship Award 2024.
December 2023: Congratulations to Nilesh on receiving an ASH Abstract Achievement Award from the American Society of Hematology at the 65th ASH Annual Meeting and Exposition, San Diego, CA.
October 2023: Congratulations to Nilesh on being selected for an oral presentation entitled “Interactions Between Integrin α9β1 and VCAM-1 Promote Neutrophil Hyperactivation and Deep Vein Thrombosis in a Murine Model of Lung Cancer” at the 65th ASH Annual Meeting and Exposition, San Diego, CA.
September 2023: Congratulations to Harpreet Kaur on receiving First Prize in the BRAID Conference poster presentation.
July 2023: Congratulations to Harpreet Kaur on receiving the CCDS Malcolm Feist Postdoctoral Fellowship.
March 2023: Congratulations to Harpreet Kaur on receiving Third Prize in the Malcolm Feist CCDS poster presentation.

Research

The Dhanesha Laboratory employs a robust, multidisciplinary approach to address critical questions in cerebrovascular diseases and thrombosis. We strategically combine data from human samples, sophisticated in vitro assays, and relevant preclinical models of both ischemic stroke and venous thrombosis to ensure translational impact.

Our current research portfolio is focused on four mechanistic and translational pillars:

Venous Thrombosis Pathogenesis: Defining novel mechanisms driving venous thrombosis, particularly in complex conditions such as lung cancer and metabolic dysfunction-associated steatohepatitis (MASH).
Stroke and Liver Crosstalk: Elucidating the bi-directional signaling between the brain and liver to identify and validate therapeutic targets that optimize stroke recovery and outcomes.
DVT Resolution: Developing cutting-edge strategies to improve the efficiency and quality of thrombus resolution following deep vein thrombosis (DVT).
Cellular Mechanisms: Investigating the essential mechanistic role of neutrophil integrin α9β1 in the pathogenesis of venous thrombosis under conditions of stroke and obesity.

These research endeavors has consistently generated high-impact results, accelerating the identification of new therapeutic targets for to improves outcomes in stroke and thrombosis. This work has successfully translated into extramural funding, patent applications, and 54 publications—including 17 as first author and 6 as corresponding author—in leading journals in thrombosis and vascular biology (Blood, Circulation, Circ Res, Stroke, JCI, ATVB, Sci Transl Med). This work has been recognized globally through invited talks, presentations at international scientific meetings, and a record of highly competitive awards.

Publications

Selected from 54 publications, 17 as first author, 6 as corresponding author.
Complete List of Published Work in My Bibliography

#Corresponding/senior author

Kaur H, Pandey N, Chandaluri L, Shaaban N, Kumar D, Pandit R, Martinez A, Anand SK, Das S, Rohilla S, Arias F, Reece E, Gaddam RR, Murnane KS, Vikram A, Mohandas R, Zhang X, Bhuiyan MAN, Lu XH, Orr AW, Rom O, Yurdagul A Jr, Dhanesha N^#. Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery After Subarachnoid Hemorrhage. Arterioscler Thromb Vasc Biol. 2025 Jul 31:10.1161/ATVBAHA.125.323072. PMID: 40740133.
Pandey N, Kaur H, Chorawala MR, Anand SK, Chandaluri L, Butler ME, Aishwarya R, Gaddam SJ, Shen X, Alfaidi M, Wang J, Zhang X, Beedupalli K, Bhuiyan MS, Bhuiyan MAN, Buchhanolla P, Rai P, Shah R, Chokhawala H, Jordan JD, Magdy T, Orr AW, Stokes KY, Rom O, Dhanesha N^#. Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT. Blood Adv. 2024 May 14;8(9):2104-2117. PMID: 38498701. Featured as the Cover story in Blood Advances, volume 8, issue 9.
Kaur H, Pandey N, Chandaluri L, Shaaban N, Martinez A, Kidder E, Patel VJ, Kshirsagar SG, Kumar D, Frausto L, Pandit R, Richard KSE, Anand SK, Das S, Vikram A, Magdy T, Lu XH, Orr AW, Patel H, Trivedi RK, Kansagra K, Joharapurkar AA, Parmar DV, Jain MR, Rom O, Yurdagul A Jr, Dhanesha N^#. Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease. Exp Neurol. 2025 Apr;386:115181. PMID: 39914641.
Pandey N, Anand SK, Kaur H, Richard KSE, Chandaluri L, Butler ME, Zhang X, Pearson-Gallion B, Rohilla S, Das S, Magdy T, Sethu P, Núñez KG, Orr AW, Stokes KY, Thevenot PT, Cohen AJ, Rom O, Dhanesha N#. Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis. J Thromb Haemost. 2024 Dec;22(12):3572-3580. PMID: 39306095.
Dhanesha N^#, Jain M, Doddapattar P, Undas A, Chauhan AK. Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice. J Thromb Haemost. 2021 Mar;19(3):814-821. PMID: 33300307
Dhanesha N, Nayak MK, Doddapattar P, Jain M, Flora GD, Kon S, Chauhan AK. Targeting myeloid-cell specific integrin α9β1 inhibits arterial thrombosis in mice. Blood. 2020 Mar 12;135(11):857-861. PMID: 31951649.
Dhanesha N, Jain M, Tripathi AK, Doddapattar P, Chorawala M, Bathla G, Nayak MK, Ghatge M, Lentz SR, Kon S, Chauhan AK. Targeting Myeloid-Specific Integrin α9β1 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. Circ Res. 2020 Jun 5;126(12):1779-1794. PMID: 32195632.
Dhanesha N, Ahmad A, Prakash P, Doddapattar P, Lentz SR, Chauhan AK. Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. Circulation. 2015 Dec 8;132(23):2237-47. PMID: 26508731 Editorial in Circulation. Messina LM. Toward a Biological Therapy to Improve Stroke Outcomes After Thrombolytic Therapy. Circulation. 2015 Dec 8;132(23):2201-2
Dhanesha N, Chorawala MR, Jain M, Bhalla A, Thedens D, Nayak M, Doddapattar P, Chauhan AK. Fn-EDA (Fibronectin Containing Extra Domain A) in Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation. Stroke. 2019 May;50(5):1201-1209. PMID: 30909835
Dhanesha N, Prakash P, Doddapattar P, Khanna I, Pollpeter MJ, Nayak MK, Staber JM, Chauhan AK. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation. Arterioscler Thromb Vasc Biol. 2016;36(9):1829‐1837. PMID: 27444201
Dhanesha N, Schnell T, Rahmatalla S, DeShaw J, Thedens D, Parker BM, Zimmerman MB, Pieper AA, Chauhan AK, Leira EC. Low-Frequency Vibrations Enhance Thrombolytic Therapy and Improve Stroke Outcomes. Stroke. 2020 Jun;51(6):1855-1861. PMID: 32397935.

Team

Nirav Dhanesha, PhD
Principal Investigator
nirav.dhanesha@lsuhs.edu

The Dhanesha Lab is dedicated to combating the life-threatening impact of venous thromboembolism (VTE) and Cerebrovascular disease. Our long-term pharmacological research is centered on a clear, vital vision: to fundamentally rewrite the treatment paradigm by fully elucidating the mechanistic core of thrombo-inflammation.We utilize a robust, multi-stage translational approach:
Discovery: Leveraging crucial human biological samples for the unbiased identification of novel therapeutic targets.
Validation: Rigorously testing and validating these targets using sophisticated in vivo and in vitro experimental models.
Translation: Identifying and developing safe, effective, and transformative therapeutic strategies that promise better long-term outcomes for patients affected by VTE and stroke.

Our mission is to translate molecular insights into clinical reality, improving patient survival and quality of life.